Screener
Theravance Biopharma TBPH Total Revenue
Total Revenue at other companies
Segments
Other financials
Where this comes from
Reported directly by Theravance Biopharma in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The source filing: Theravance Biopharma’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 9:00 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001104659-26-056760
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Revenues: | ||
| Viatris collaboration agreement | $17,699 | $15,388 |
| Total revenues | 17,699 | 15,388 |
| Expenses: | ||
| Research and development (1) | 5,829 | 11,452 |
| Selling, general and administrative (1) | 17,720 | 18,370 |
| Restructuring expenses (1) (2) | 3,633 | — |
| Total expenses | 27,182 | 29,822 |
Item 1. Financial Statements (unaudited)
FAQ
- What is Theravance Biopharma's total revenue?
- Theravance Biopharma (TBPH) reported total revenue of $17.7M in Q1 2026.
- How has Theravance Biopharma's total revenue changed year-over-year?
- Theravance Biopharma's total revenue increased by 15.0% year-over-year, from $15.39M to $17.7M.
- What is the long-term trend for Theravance Biopharma's total revenue?
- Over 4 years (2021 to 2025), Theravance Biopharma's total revenue has grown at a 18.1% compound annual growth rate (CAGR), from $55.31M to $107.46M.
- What does total revenue mean?
- The aggregate of all revenue from the company's operations — the top line from which all profitability metrics are derived.
Ask your AI about Theravance Biopharma's total revenue.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude